Stockreport

Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV

SPRING BANK PHARMACEUTICALS  (SBPH) 
Last spring bank pharmaceuticals earnings: 11/7 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.springbankpharm.com/investor-overview
PDF Continuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCsAdjusting cost s [Read more]